Pier Capital’s Neumora Therapeutics NMRA Stock Holding History

Pier Capital’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-249,336	Closed	-$3.43M	–	131
2024 Q1	$3.43M	Buy	+249,336	New	+$4.03M	0.47%	91

Other funds holding NMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Pier Capital's NMRA Position: Q2 2024 in Review

Pier Capital sold out of Neumora Therapeutics (NMRA) in Q2 2024, closing a stake of 249,336 shares — an estimated $3.43M sold.

Pier Capital first reported a position in NMRA in Q1 2024 and held it in 1 quarter. The position peaked at $3.43M in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q2 2024.

Pier Capital reported no remaining Neumora Therapeutics position as of Q2 2024 after selling out during the quarter.
Pier Capital sold 249,336 Neumora Therapeutics shares in Q2 2024, an estimated $3.43M.
Pier Capital first reported a position in Neumora Therapeutics in Q1 2024 and held it in 1 quarter.
Pier Capital's Neumora Therapeutics position peaked at $3.43M in Q1 2024.
93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2024.

Based on Pier Capital's 13F filing for Q2 2024, filed 7 Aug 2024.